# Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)

> **NCT01539291** · PHASE3 · TERMINATED · sponsor: **Gilead Sciences** · enrollment: 161 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Idelalisib

## Key facts

- **NCT ID:** NCT01539291
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-10-03
- **Primary completion:** 2018-05-21
- **Final completion:** 2018-06-29
- **Target enrollment:** 161 (ACTUAL)
- **Last updated:** 2019-08-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01539291

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01539291, "Extension Study of Idelalisib in Participants With Chronic Lymphocytic Leukemia (CLL) Who Participated in GS-US-312-0116 (NCT01539512)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01539291. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*